Cardio Care Live

CME Speakers

PCSK9 Inhibitors and CV Risk Reduction

  • Michael J. Blaha, MD, MPH

    Michael J. Blaha, MD, MPH

    Michael J. Blaha, MD, MPH

    Director of Clinical Research, Ciccarone Center for the Prevention of Heart Disease; Assistant Professor of Medicine

    Michael J. Blaha, MD, MPH, is director of clinical research for the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease in Baltimore, Maryland, and assistant professor of medicine at the Johns Hopkins Bloomberg School of Public Health. A practicing preventive noninvasive cardiologist, his work includes improving cardiovascular risk prediction through novel methods of early detection of atherosclerosis, including the use of cardiac computed tomography Dr Blaha is an associate editor for the journal Atherosclerosis, has published over 250 original papers, and two books on the metabolic syndrome. He is a founding member of The FIT Project, a principal investigator of the Coronary Artery Calcium Consortium, and co-director of the mobile health mActive Program at Johns Hopkins.
  • Michael Miller, MD, FACC, FAHA

    Michael Miller, MD, FACC, FAHA

    Michael Miller, MD, FACC, FAHA

    Professor of Cardiovascular Medicine, Epidemiology & Public Health

    Michael Miller, MD, FACC, FAHA, is professor of medicine at the University of Maryland School of Medicine in Baltimore and director of the Center for Preventive Cardiology for the University of Maryland Medical System. Dr Miller’s main research interests are disorders of lipid and lipoprotein metabolism; molecular studies of HDL cholesterol, triglycerides, and the postprandial response to dietary fat; nontraditional coronary risk factors; and clinical trials to reduce atherosclerosis. He serves on the Leadership Council of the American Heart Association (AHA), is a member of the AHA Nutrition and Lifestyle Committee, is past president of the American Society of Preventive Cardiology, and has published more than 250 scientific papers in leading medical journals such as JACC and JAMA.
  • Marc S. Sabatine, MD, MPH

    Marc S. Sabatine, MD, MPH

    Marc S. Sabatine, MD, MPH

    Lewis Dexter, MD Distinguished Chair in Cardiovascular Medicine

    Marc S. Sabatine, MD, MPH, is chairman of the Thrombolysis in Myocardial Infarction (TIMI) Study Group, the Lewis Dexter, MD, Distinguished Chair in Cardiovascular Medicine at Brigham and Women’s Hospital, and a professor of medicine at Harvard Medical School in Boston, Massachusetts. As chairman of the TIMI Study Group, Dr Sabatine leads an academic research organization whose mission is to advance the knowledge and care of patients suffering from cardiovascular disease and its risk factors. He has led several large-scale, international, randomized controlled trials of novel antithrombotic, lipid-lowering and other pharmacotherapies, has a long-standing interest in pharmacogenetics, and has made seminal observations on the ability to use genetics for personalized medicine.

Cardiovascular Disease, Diabetes, and Diabetes Treatments

  • Donald E. Cutlip, MD

    Donald E. Cutlip, MD

    Donald E. Cutlip, MD

    Section Chief, Interventional Cardiology

    Donald E. Cutlip, MD, is section chief of interventional cardiology and director of the Cardiac Catheterization Laboratory at Beth Israel Deaconess Medical Center, professor of medicine at Harvard Medical School, and a senior investigator at the Baim Institute for Clinical Research in Boston, Massachusetts. His clinical activities focus on coronary and valvular interventions, with a special interest in cardiovascular disease in patients with diabetes. He is involved in the design and management of numerous clinical trials of coronary, valvular, and peripheral vascular interventions. Dr Cutlip founded the Academic Research Consortium, and was a member of the ACC/AHA Task Force’s writing committee for key data elements and definitions for cardiovascular endpoint events in clinical trials.
  • Richard Beaser, MD

    Richard Beaser, MD

    Richard Beaser, MD

    Senior Physician, Medical Director, Professional Education

    Richard S. Beaser, M.D., is a practicing physician in the Joslin Clinic and holds the position of Associate Clinical Professor of Medicine at Harvard Medical School. He has also been the Medical Executive Director of Professional Education at Joslin and was instrumental in developing that activity at Joslin, a department he founded in 1990. Dr. Beaser graduated in 1973 from Trinity College, Hartford, and received his medical degree from Boston University School of Medicine in 1977. He served as a resident in internal medicine at the University of Massachusetts Medical Center in Worcester from 1977-1980. He was a fellow in endocrinology at the Joslin Diabetes Center, Boston, MA 1980-81, and in Endocrinology at the Lahey Clinic Medical Center, Burlington, MA 1981-82. Dr. Beaser has been on the staff of the Joslin Diabetes Center since 1982. He has held numerous past positions at Joslin, including Section Chief of the Adult Diabetology Practice, Medical Director of the Diabetes Treatment Unit, Coordinator of the Patient Education Section, and Medical Director of Joslin TrialNet, a clinical trials network. He has been a clinical research investigator, including the landmark Diabetes Control and Complications Trial. Dr. Beaser has authored 4 books: Joslin Diabetes Manual, Outsmarting Diabetes, The Joslin Guide to Diabetes, and Joslin’s Diabetes Deskbook: A Guide for Primary Care Providers. Dr Beaser is a well-known national lecturer on clinical diabetes and its comorbidities. He is the author of numerous publications in peer review journals, review articles, and book chapters. In his role as Medical Executive Director of Professional Education at Joslin Diabetes Center, and currently as the Chair of the CME Committee, Dr. Beaser has a specific focus on development or oversight of educational content for the department, targeting physicians, other medical professionals, and patients. He leads departmental conceptualization and development of projects and activities.
  • Vivian A. Fonseca, MD, FRCP

    Vivian A. Fonseca, MD, FRCP

    Vivian A. Fonseca, MD, FRCP

    Professor of Medicine and Pharmacology; Chief, Section of Endocrinology

    Vivian A. Fonseca, MD, FRCP, is a professor of medicine and pharmacology, the Tullis-Tulane Alumni Chair in Diabetes, and chief, Section of Endocrinology, at Tulane University Health Sciences Center in New Orleans, Louisiana. His current research interests include the prevention and treatment of diabetic complications and risk factor reduction in cardiovascular disease. Dr Fonseca is a fellow of the American Association of Clinical Endocrinologists, the Royal College of Physicians (London) and the American College of Physicians, and is a member of the Endocrine Society, the American Diabetes Association, and the International Diabetes Federation. He serves on numerous national and international committees, and has published more than 200 papers, review articles and book chapters.
  • Robert E. Heinig, MD

    Robert E. Heinig, MD

    Robert E. Heinig, MD

    Director, Vascular Disease Prevention Program

    Robert E. Heinig, MD, is clinical professor of medicine at the University of Rochester Medical School and director of the Vascular Diabetes Prevention Program at Rochester General Hospital in Rochester, New York. His current research interests include genetic and disease-related hyperlipidemia, normocholesterolemic dyslipidemia in insulin-resistant patients predisposing to coronary heart disease, and multiple risk factor modification in diabetic and insulin resistant patients with coronary heart disease. He belongs to several professional societies, including the American Diabetes Association, Endocrine Society, the American Society of Nephrology, and the American Association of Clinical Endocrinologists. Dr Heinig earned his MD from the University of Oregon School of Medicine in Portland.
  • Michael Rocco, MD

    Michael Rocco, MD

    Michael Rocco, MD

    Medical Director of Stress Testing and Cardiac Rehabilitation

    Michael Rocco, MD, is medical director of Cardiac Rehabilitation and Stress Testing, section of preventive cardiology, and a staff physician in the Departments of Cardiovascular Medicine and Molecular and Functional Imaging in the Division of Radiology at Cleveland Clinic in Ohio. His clinical research focuses primarily on the prognostic significance of asymptomatic ischemia, the evaluation of therapeutic interventions and exercise in the treatment and prevention of coronary artery disease, and the effect of drug therapy on lowering lipid levels. Dr Rocco lectures regionally and nationally, has published articles and abstracts in leading medical journals, and has authored chapters in textbooks. He received his medical degree from Duke University Medical Center in Durham, North Carolina.
  • Stephen A. Brunton, MD, FAAFP

    Stephen A. Brunton, MD, FAAFP

    Stephen A. Brunton, MD, FAAFP

    Executive Vice President

    Stephen Brunton, MD, FAAFP, is the executive vice president for education for the Primary Care Education Consortium, works in a group practice in Los Angeles, California, and is an adjunct clinical professor in the Department of Pharmacy Practice at Roseman University of Health Sciences in Salt Lake City, Utah. A board-certified family physician with a certificate of added qualifications in geriatrics, he earned his MD at Monash University Medical School in Melbourne, Australia. He is the former president of the California Academy of Family Physicians and the Association of Family Medicine Residency Directors. Dr Brunton has published numerous articles, chapters, and monographs on family medicine and related clinical topics, and serves in editorial capacities for numerous journals.
  • Om P. Ganda, MD

    Om P. Ganda, MD

    Om P. Ganda, MD

    Medical Director of the Lipid Clinic, Chair of the Clinical Oversight Committee

    Om P. Ganda, MD, FACE, is a board-certified specialist in internal medicine, endocrinology and metabolism, and clinical nutrition. He is a senior physician at the Joslin Diabetes Center and an associate professor of medicine at Harvard Medical School in Boston, Massachusetts. A co-investigator in the Diabetes Control and Complications Trial (DCCT), he has been engaged in clinical diabetes research for more than 3 decades. He is co-investigator of Epidemiology of Diabetes Interventions and Complications (EDIC), an ongoing, long-term, follow-up study. In addition to his clinical research and teaching, he directs the Lipid Clinic at Joslin, where he treats complex patients with dyslipidemia. Dr Ganda received his MD from the SMS Medical College, University of Rajasthan, Jaipur, India.

Heart Failure

  • Akshay Suvas Desai, MD, MPH

    Akshay Suvas Desai, MD, MPH

    Akshay Suvas Desai, MD, MPH

    Associate Professor of Medicine

    Jagmeet P. Singh, MD, PhD, is a professor of medicine at Harvard Medical School and the associate chief of the Cardiology Division at Massachusetts General Hospital, both located in Boston. He is also the founder and the director of the Resynchronization and Advanced Cardiac Therapeutics Program. His research interests are in clinical cardiac electrophysiology, with an emphasis on device therapy for heart failure and catheter ablation of atrial fibrillation. He is the principal investigator and a member of steering committees for over 20 active single- and multi-center research studies. Dr Singh earned his MD from BJ Medical College, Pune University, India, and completed his internal medicine residency, cardiology and cardiac electrophysiology fellowships at Massachusetts General Hospital.
  • James L. Januzzi, Jr., MD, FACC, FESC

    James L. Januzzi, Jr., MD, FACC, FESC

    James L. Januzzi, Jr., MD, FACC, FESC

    Professor of Medicine

    James L. Januzzi, MD, is the Hutter Family Professor of Medicine at Harvard Medical School and a faculty member at the Harvard Clinical Research Institute. His research has contributed to the understanding of cardiac biomarker testing, where his studies have set international standards for use in diagnosis, prognosis, and management of patients suffering from acutely decompensated heart failure, chronic heart failure as well as those with acute coronary syndromes. Dr Januzzi has published numerous manuscripts, book chapters and review articles, and has edited two text books on cardiac biomarker testing. He serves on the editorial board of numerous scientific journals, and is currently the chair of the ACC Task Force on Consensus Statements. He earned his MD from New York Medical College.
  • Jagmeet Singh, MD, DPhil, FHRS

    Jagmeet Singh, MD, DPhil, FHRS

    Jagmeet Singh, MD, DPhil, FHRS

    Professor of Medicine

    Jagmeet P. Singh, MD, PhD, is a professor of medicine at Harvard Medical School and the associate chief of the Cardiology Division at Massachusetts General Hospital, both located in Boston. He is also the founder and the director of the Resynchronization and Advanced Cardiac Therapeutics Program. His research interests are in clinical cardiac electrophysiology, with an emphasis on device therapy for heart failure and catheter ablation of atrial fibrillation. He is the principal investigator and a member of steering committees for over 20 active single- and multi-center research studies. Dr Singh earned his MD from BJ Medical College, Pune University, India, and completed his internal medicine residency, cardiology and cardiac electrophysiology fellowships at Massachusetts General Hospital.

All Speakers

  • Michael J. Blaha, MD, MPH

    Michael J. Blaha, MD, MPH

    Michael J. Blaha, MD, MPH

    Director of Clinical Research, Ciccarone Center for the Prevention of Heart Disease; Assistant Professor of Medicine

    Michael J. Blaha, MD, MPH, is director of clinical research for the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease in Baltimore, Maryland, and assistant professor of medicine at the Johns Hopkins Bloomberg School of Public Health. A practicing preventive noninvasive cardiologist, his work includes improving cardiovascular risk prediction through novel methods of early detection of atherosclerosis, including the use of cardiac computed tomography Dr Blaha is an associate editor for the journal Atherosclerosis, has published over 250 original papers, and two books on the metabolic syndrome. He is a founding member of The FIT Project, a principal investigator of the Coronary Artery Calcium Consortium, and co-director of the mobile health mActive Program at Johns Hopkins.
  • Michael Miller, MD, FACC, FAHA

    Michael Miller, MD, FACC, FAHA

    Michael Miller, MD, FACC, FAHA

    Professor of Cardiovascular Medicine, Epidemiology & Public Health

    Michael Miller, MD, FACC, FAHA, is professor of medicine at the University of Maryland School of Medicine in Baltimore and director of the Center for Preventive Cardiology for the University of Maryland Medical System. Dr Miller’s main research interests are disorders of lipid and lipoprotein metabolism; molecular studies of HDL cholesterol, triglycerides, and the postprandial response to dietary fat; nontraditional coronary risk factors; and clinical trials to reduce atherosclerosis. He serves on the Leadership Council of the American Heart Association (AHA), is a member of the AHA Nutrition and Lifestyle Committee, is past president of the American Society of Preventive Cardiology, and has published more than 250 scientific papers in leading medical journals such as JACC and JAMA.
  • Marc S. Sabatine, MD, MPH

    Marc S. Sabatine, MD, MPH

    Marc S. Sabatine, MD, MPH

    Lewis Dexter, MD Distinguished Chair in Cardiovascular Medicine

    Marc S. Sabatine, MD, MPH, is chairman of the Thrombolysis in Myocardial Infarction (TIMI) Study Group, the Lewis Dexter, MD, Distinguished Chair in Cardiovascular Medicine at Brigham and Women’s Hospital, and a professor of medicine at Harvard Medical School in Boston, Massachusetts. As chairman of the TIMI Study Group, Dr Sabatine leads an academic research organization whose mission is to advance the knowledge and care of patients suffering from cardiovascular disease and its risk factors. He has led several large-scale, international, randomized controlled trials of novel antithrombotic, lipid-lowering and other pharmacotherapies, has a long-standing interest in pharmacogenetics, and has made seminal observations on the ability to use genetics for personalized medicine.
  • Donald E. Cutlip, MD

    Donald E. Cutlip, MD

    Donald E. Cutlip, MD

    Section Chief, Interventional Cardiology

    Donald E. Cutlip, MD, is section chief of interventional cardiology and director of the Cardiac Catheterization Laboratory at Beth Israel Deaconess Medical Center, professor of medicine at Harvard Medical School, and a senior investigator at the Baim Institute for Clinical Research in Boston, Massachusetts. His clinical activities focus on coronary and valvular interventions, with a special interest in cardiovascular disease in patients with diabetes. He is involved in the design and management of numerous clinical trials of coronary, valvular, and peripheral vascular interventions. Dr Cutlip founded the Academic Research Consortium, and was a member of the ACC/AHA Task Force’s writing committee for key data elements and definitions for cardiovascular endpoint events in clinical trials.
  • Richard Beaser, MD

    Richard Beaser, MD

    Richard Beaser, MD

    Senior Physician, Medical Director, Professional Education

    Richard S. Beaser, M.D., is a practicing physician in the Joslin Clinic and holds the position of Associate Clinical Professor of Medicine at Harvard Medical School. He has also been the Medical Executive Director of Professional Education at Joslin and was instrumental in developing that activity at Joslin, a department he founded in 1990. Dr. Beaser graduated in 1973 from Trinity College, Hartford, and received his medical degree from Boston University School of Medicine in 1977. He served as a resident in internal medicine at the University of Massachusetts Medical Center in Worcester from 1977-1980. He was a fellow in endocrinology at the Joslin Diabetes Center, Boston, MA 1980-81, and in Endocrinology at the Lahey Clinic Medical Center, Burlington, MA 1981-82. Dr. Beaser has been on the staff of the Joslin Diabetes Center since 1982. He has held numerous past positions at Joslin, including Section Chief of the Adult Diabetology Practice, Medical Director of the Diabetes Treatment Unit, Coordinator of the Patient Education Section, and Medical Director of Joslin TrialNet, a clinical trials network. He has been a clinical research investigator, including the landmark Diabetes Control and Complications Trial. Dr. Beaser has authored 4 books: Joslin Diabetes Manual, Outsmarting Diabetes, The Joslin Guide to Diabetes, and Joslin’s Diabetes Deskbook: A Guide for Primary Care Providers. Dr Beaser is a well-known national lecturer on clinical diabetes and its comorbidities. He is the author of numerous publications in peer review journals, review articles, and book chapters. In his role as Medical Executive Director of Professional Education at Joslin Diabetes Center, and currently as the Chair of the CME Committee, Dr. Beaser has a specific focus on development or oversight of educational content for the department, targeting physicians, other medical professionals, and patients. He leads departmental conceptualization and development of projects and activities.
  • Vivian A. Fonseca, MD, FRCP

    Vivian A. Fonseca, MD, FRCP

    Vivian A. Fonseca, MD, FRCP

    Professor of Medicine and Pharmacology; Chief, Section of Endocrinology

    Vivian A. Fonseca, MD, FRCP, is a professor of medicine and pharmacology, the Tullis-Tulane Alumni Chair in Diabetes, and chief, Section of Endocrinology, at Tulane University Health Sciences Center in New Orleans, Louisiana. His current research interests include the prevention and treatment of diabetic complications and risk factor reduction in cardiovascular disease. Dr Fonseca is a fellow of the American Association of Clinical Endocrinologists, the Royal College of Physicians (London) and the American College of Physicians, and is a member of the Endocrine Society, the American Diabetes Association, and the International Diabetes Federation. He serves on numerous national and international committees, and has published more than 200 papers, review articles and book chapters.
  • Robert E. Heinig, MD

    Robert E. Heinig, MD

    Robert E. Heinig, MD

    Director, Vascular Disease Prevention Program

    Robert E. Heinig, MD, is clinical professor of medicine at the University of Rochester Medical School and director of the Vascular Diabetes Prevention Program at Rochester General Hospital in Rochester, New York. His current research interests include genetic and disease-related hyperlipidemia, normocholesterolemic dyslipidemia in insulin-resistant patients predisposing to coronary heart disease, and multiple risk factor modification in diabetic and insulin resistant patients with coronary heart disease. He belongs to several professional societies, including the American Diabetes Association, Endocrine Society, the American Society of Nephrology, and the American Association of Clinical Endocrinologists. Dr Heinig earned his MD from the University of Oregon School of Medicine in Portland.
  • Michael Rocco, MD

    Michael Rocco, MD

    Michael Rocco, MD

    Medical Director of Stress Testing and Cardiac Rehabilitation

    Michael Rocco, MD, is medical director of Cardiac Rehabilitation and Stress Testing, section of preventive cardiology, and a staff physician in the Departments of Cardiovascular Medicine and Molecular and Functional Imaging in the Division of Radiology at Cleveland Clinic in Ohio. His clinical research focuses primarily on the prognostic significance of asymptomatic ischemia, the evaluation of therapeutic interventions and exercise in the treatment and prevention of coronary artery disease, and the effect of drug therapy on lowering lipid levels. Dr Rocco lectures regionally and nationally, has published articles and abstracts in leading medical journals, and has authored chapters in textbooks. He received his medical degree from Duke University Medical Center in Durham, North Carolina.
  • Stephen A. Brunton, MD, FAAFP

    Stephen A. Brunton, MD, FAAFP

    Stephen A. Brunton, MD, FAAFP

    Executive Vice President

    Stephen Brunton, MD, FAAFP, is the executive vice president for education for the Primary Care Education Consortium, works in a group practice in Los Angeles, California, and is an adjunct clinical professor in the Department of Pharmacy Practice at Roseman University of Health Sciences in Salt Lake City, Utah. A board-certified family physician with a certificate of added qualifications in geriatrics, he earned his MD at Monash University Medical School in Melbourne, Australia. He is the former president of the California Academy of Family Physicians and the Association of Family Medicine Residency Directors. Dr Brunton has published numerous articles, chapters, and monographs on family medicine and related clinical topics, and serves in editorial capacities for numerous journals.
  • Om P. Ganda, MD

    Om P. Ganda, MD

    Om P. Ganda, MD

    Medical Director of the Lipid Clinic, Chair of the Clinical Oversight Committee

    Om P. Ganda, MD, FACE, is a board-certified specialist in internal medicine, endocrinology and metabolism, and clinical nutrition. He is a senior physician at the Joslin Diabetes Center and an associate professor of medicine at Harvard Medical School in Boston, Massachusetts. A co-investigator in the Diabetes Control and Complications Trial (DCCT), he has been engaged in clinical diabetes research for more than 3 decades. He is co-investigator of Epidemiology of Diabetes Interventions and Complications (EDIC), an ongoing, long-term, follow-up study. In addition to his clinical research and teaching, he directs the Lipid Clinic at Joslin, where he treats complex patients with dyslipidemia. Dr Ganda received his MD from the SMS Medical College, University of Rajasthan, Jaipur, India.
  • Akshay Suvas Desai, MD, MPH

    Akshay Suvas Desai, MD, MPH

    Akshay Suvas Desai, MD, MPH

    Associate Professor of Medicine

    Jagmeet P. Singh, MD, PhD, is a professor of medicine at Harvard Medical School and the associate chief of the Cardiology Division at Massachusetts General Hospital, both located in Boston. He is also the founder and the director of the Resynchronization and Advanced Cardiac Therapeutics Program. His research interests are in clinical cardiac electrophysiology, with an emphasis on device therapy for heart failure and catheter ablation of atrial fibrillation. He is the principal investigator and a member of steering committees for over 20 active single- and multi-center research studies. Dr Singh earned his MD from BJ Medical College, Pune University, India, and completed his internal medicine residency, cardiology and cardiac electrophysiology fellowships at Massachusetts General Hospital.
  • James L. Januzzi, Jr., MD, FACC, FESC

    James L. Januzzi, Jr., MD, FACC, FESC

    James L. Januzzi, Jr., MD, FACC, FESC

    Professor of Medicine

    James L. Januzzi, MD, is the Hutter Family Professor of Medicine at Harvard Medical School and a faculty member at the Harvard Clinical Research Institute. His research has contributed to the understanding of cardiac biomarker testing, where his studies have set international standards for use in diagnosis, prognosis, and management of patients suffering from acutely decompensated heart failure, chronic heart failure as well as those with acute coronary syndromes. Dr Januzzi has published numerous manuscripts, book chapters and review articles, and has edited two text books on cardiac biomarker testing. He serves on the editorial board of numerous scientific journals, and is currently the chair of the ACC Task Force on Consensus Statements. He earned his MD from New York Medical College.
  • Jagmeet Singh, MD, DPhil, FHRS

    Jagmeet Singh, MD, DPhil, FHRS

    Jagmeet Singh, MD, DPhil, FHRS

    Professor of Medicine

    Jagmeet P. Singh, MD, PhD, is a professor of medicine at Harvard Medical School and the associate chief of the Cardiology Division at Massachusetts General Hospital, both located in Boston. He is also the founder and the director of the Resynchronization and Advanced Cardiac Therapeutics Program. His research interests are in clinical cardiac electrophysiology, with an emphasis on device therapy for heart failure and catheter ablation of atrial fibrillation. He is the principal investigator and a member of steering committees for over 20 active single- and multi-center research studies. Dr Singh earned his MD from BJ Medical College, Pune University, India, and completed his internal medicine residency, cardiology and cardiac electrophysiology fellowships at Massachusetts General Hospital.